← Back to Search

Retinoid

CD5789 (trifarotene) 50μg/g Cream for Acne Vulgaris

Phase 3
Waitlist Available
Led By Jerry Tan, MD
Research Sponsored by Galderma R&D
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to week 12
Awards & highlights
All Individual Drugs Already Approved
Pivotal Trial

Summary

Assessment of the efficacy and safety of CD5789 (trifarotene) 50μg/g cream applied once daily for 12 weeks in subjects with acne vulgaris.

Eligible Conditions
  • Acne Vulgaris
  • Acne

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and from baseline to week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Investigator Global Assessment (IGA) Success Rate at Week 12

Side effects data

From 2017 Phase 3 trial • 1208 Patients • NCT02566369
11%
Application Site Irritation
4%
Application Site Pruritis
4%
Sunburn
4%
Nasopharyngitis
2%
Upper Respiratory Tract Infection
1%
Skin Irritation
1%
Sinusitis
1%
Influenza
1%
Headache
100%
80%
60%
40%
20%
0%
Study treatment Arm
CD5789 (Trifarotene) 50μg/g Cream
Placebo Cream

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CD5789 (trifarotene) 50μg/g CreamExperimental Treatment1 Intervention
CD5789 (trifarotene) 50μg/g Cream
Group II: Placebo CreamPlacebo Group1 Intervention
Placebo cream
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Trifarotene
FDA approved

Find a Location

Who is running the clinical trial?

Galderma R&DLead Sponsor
302 Previous Clinical Trials
59,479 Total Patients Enrolled
47 Trials studying Acne Vulgaris
14,315 Patients Enrolled for Acne Vulgaris
Jerry Tan, MDPrincipal InvestigatorWindsor Clinical Research
2 Previous Clinical Trials
383 Total Patients Enrolled
1 Trials studying Acne Vulgaris
123 Patients Enrolled for Acne Vulgaris
Ulrike Blume-Peytavi, MDPrincipal InvestigatorCharité Universitätsmedizin
~122 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top